EUVIMEDEUVIMED entdecken
Multizentrische Studie

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India

Vamshi Krishna Muddu iD, Anjali Shah, Anupa John iD, Abhishek Raj, Ankur Bahl iD, Senthil J Rajappa, Thirumalairaj Raja iD, Joydeep Ghosh iD, Viraj Lavingia iD, Amish Vora, Prabhat Bhargava iD, Anant Ramaswamy iD und 13 weitere

JCO Global Oncology · 2024-12 · (10)

DOI: 10.1200/go.24.00216 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2024-12. Verfasst von Vamshi Krishna Muddu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Institute of Oncology, AIG Hospitals, Hyderabad, India. Hauptthemen laut MEDLINE: Deoxycytidine, Gemcitabine, Biliary Tract Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Biliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TOPAZ-1 trial demonstrated a 24% decrease in risk of death at 2 years with the addition of durvalumab to chemotherapy. MATERIALS AND METHODS This was a multicenter retrospective cohort study conducted across 14 institutions in India. All the patients were diagnosed with advanced BTCs. The primary objective was to assess median overall survival (mOS) with the use of durvalumab in combination with chemotherapy backbone. The patient details, treatment details, laboratory results, and outcome parameters were recorded from the prospectively collected databases. RESULTS A total of 148 patients were included with a median age of 57.5 years; 36 (24.3%) patients had borderline Eastern Cooperative Oncology Group performance status ≥2. The most common subtype was gall bladder cancer (GBC), seen in 94 patients (63.5%); 126 (85.1%) patients presented with de novo metastases. At a median follow-up of 6.8 months (95% CI, 5.9 to 7.8), the estimated mOS for the entire cohort was 12 months (95% CI, 7.8 to 16.3) and median progression-free survival was 8.2 months (95% CI, 7.1 to 9.4) with objective response achieved in 44 (29.7%) patients, and the estimated 2-year OS being 25%. Immune-related grade 3/4 adverse events were reported in 11 (7.4%) patients. In multivariate analysis, age 60 years and low dose of durvalumab. CONCLUSION To our knowledge, these real-world data provide the first evidence in Indian context of the efficacy and safety of durvalumab plus chemotherapy in patients with advanced/metastatic BTCs especially in GBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineGemcitabineBiliary Tract NeoplasmsAntibodies, MonoclonalCisplatinAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedIndiaRetrospective StudiesAgedAdult

Substanzen

durvalumabDeoxycytidineGemcitabineAntibodies, MonoclonalCisplatin

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Institute of Oncology, AIG Hospitals, Hyderabad, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Medical Oncology, Sarvodaya Hospital, Faridabad, India.
  • Department of Medical Oncology, Fortis Memorial Hospital, Gurgaon, India.
  • Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital & RI, Hyderabad, India.
  • Department of Medical Oncology, Apollo Cancer Hospital, Chennai, India.

ORCID-Profile: Vamshi Krishna Muddu, Anupa John, Ankur Bahl, Thirumalairaj Raja, Joydeep Ghosh, Viraj Lavingia, Prabhat Bhargava, Anant Ramaswamy, Arif Khan, Atul Sharma, Aditya Dhanawat, Manoj Mahajan, Manan Vora, Vikas S Ostwal

Zitieren

APA

Muddu, V. K., Shah, A., John, A., Raj, A., Bahl, A., Rajappa, S. J., Raja, T., Ghosh, J., Lavingia, V., Vora, A., Bhargava, P., Ramaswamy, A., Khan, A., Sharma, A., Trikha, M., Dhanawat, A., Bonda, A., Siripurapu, I., Mahajan, M., …, & Ostwal, V. S. (2024). Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India. JCO Global Oncology. https://doi.org/10.1200/go.24.00216

Vancouver

Muddu VK, Shah A, John A, Raj A, Bahl A, Rajappa SJ, et al. Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India. JCO Global Oncology. 2024. doi:10.1200/go.24.00216

BibTeX
@article{Muddu2024,
  author = {Muddu, Vamshi Krishna and Shah, Anjali and John, Anupa and Raj, Abhishek and Bahl, Ankur and Rajappa, Senthil J and Raja, Thirumalairaj and Ghosh, Joydeep and Lavingia, Viraj and Vora, Amish and Bhargava, Prabhat and Ramaswamy, Anant and Khan, Arif and Sharma, Atul and Trikha, Mehak and Dhanawat, Aditya and Bonda, Avinash and Siripurapu, Indraja and Mahajan, Manoj and Rohatgi, Nitesh and Chandrakant, Mosale Venkatesha and Gujarathi, Himanshu and Vora, Manan and Ankathi, Sumankumar and Ostwal, Vikas S},
  title = {Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India},
  journal = {JCO Global Oncology},
  year = {2024},
  number = {10},
  doi = {10.1200/go.24.00216}
}
Kostenlos starten →